Key Highlights

  • Net loss was USD 183.16 million, compared with USD 3.44 million.
  • Loss per share was USD 61.58, compared with USD 1.81.
  • Acquired in-process Research and Development expenses were USD 178.03 million.
  • Cash and cash equivalents were USD 180.21 million at September 30, 2026.

Processa Pharmaceuticals (NASDAQ:PCSA) reported a net loss of USD 183.16 million for the third quarter of 2026, compared with USD 3.44 million in the prior-year quarter. Net loss per common share, basic and diluted, was USD 61.58, compared with USD 1.81.

The filing states that the company completed the Vidya Acquisition pursuant to a Merger agreement dated July 28, 2026, and received USD 200.0 million in gross proceeds from a concurrent private Placement of non-voting convertible preferred stock.

Operating Expenses

Research and development expenses were USD 1.81 million, compared with USD 1.66 million. Acquired in-process research and development expenses were USD 178.03 million, with no comparable amount in the prior-year quarter. General and administrative expenses were USD 4.29 million, compared with USD 1.83 million.

The operating loss was USD 184.13 million, compared with USD 3.49 million. Interest income, net, was USD 1.01 million, compared with USD 46 thousand. Weighted average common shares used to compute the net loss per share were 2,974,188, compared with 1,901,098.

Nine-Month Results

For the nine months ended September 30, 2026, the net loss was USD 189.80 million, compared with USD 10.21 million, and net loss per common share was USD 68.18, compared with USD 10.48. Research and development expenses were USD 4.27 million, compared with USD 5.70 million, and general and administrative expenses were USD 7.50 million, compared with USD 4.59 million.

Balance Sheet and Financing

Cash and cash equivalents were USD 180.21 million at September 30, 2026, compared with USD 5.54 million at December 31, 2025. Total Assets were USD 182.01 million, compared with USD 7.81 million. Digital assets at Fair Value were USD 431 thousand.

The filing states that the Vidya Acquisition brought into the pipeline VT-7208, an orally available, covalently binding, irreversible, central nervous system-penetrant Bruton's tyrosine kinase inhibitor. The company states that it intends to use net proceeds of USD 187.1 million from the private placement to fund operations into the second half of 2029 and through key clinical milestones, including top-line data from Phase 2 proof-of-concept trials of VT-7208 for food allergy, chronic spontaneous urticaria and relapsing multiple sclerosis.

The filing also describes a potential cash-settlement obligation related to the Series A Preferred Stock and states that the plan is to obtain stockholder approval at a meeting anticipated in the first quarter of 2027.

The comprehensive loss was USD 183.18 million, compared with USD 3.44 million. The unrealized loss on digital assets was USD 41 thousand for the quarter and USD 869 thousand for the nine months, and the realized loss on digital assets was USD 159 thousand for the nine months. Prepaid expenses and other assets were USD 1.37 million, compared with USD 134 thousand.

The filing states that each share of the Series A Preferred Stock is convertible into 1,000 shares of common stock, subject to receiving stockholder approval of the issuance of shares of common stock upon conversion of the Series A Preferred Stock and exercise of the assumed options.

Processa Pharmaceuticals Q3 2026 Earnings: Key Takeaways

Processa Pharmaceuticals reported a third quarter 2026 net loss of USD 183.16 million and a loss per share of USD 61.58. Cash and cash equivalents were USD 180.21 million at September 30, 2026.